AUTHOR=Li Hui , Deng Yixiao , Chen Bin , Xiao Yajie , Yang Jie , Liu Qionghui , Lin Gengpeng 

TITLE=Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.913838

DOI=10.3389/fonc.2022.913838

ISSN=2234-943X

ABSTRACT=<p>Next-generation sequencing technology has enabled the identification of fusion partners of anaplastic lymphoma kinase (<italic>ALK</italic>) in non-small cell lung cancer, and various <italic>ALK</italic> fusion partners have been confirmed. Here, a novel rhabdomyosarcoma 2-associated transcript (<italic>RMST</italic>)-<italic>ALK</italic> rearrangement was identified in an 80-year-old Chinese man with advanced lung adenocarcinoma. The patient was prescribed ceritinib and achieved a partial response, which has been sustained for more than 18 months. This is the first report of the <italic>RMST-ALK</italic> rearrangement, and we showed that a patient with lung adenocarcinoma carrying this rearrangement can benefit from ceritinib treatment; therefore, this is a significant finding in clinical practice.</p>